Immunai’s digital ‘plumbing’ keeps AstraZeneca coming back

Immunai, a startup building a foundation model of the human immune system, has expanded its oncology collaboration with AstraZeneca for the third time. Immunai is eligible to receive up to $37.5 million over 2026 and 2027 under the new agreement, which extends its AMICA-OS platform deeper into AstraZeneca’s clinical development pipeline. The two companies began… The post Immunai’s digital ‘plumbing’ keeps AstraZeneca coming back appeared first on Drug Discovery and Development.

Continue reading →